MARATTO

review · Medicine

Living with sickle cell in Uganda: A comprehensive perspective on challenges, coping strategies, and health interventions

202412 citationsOpen accessKampala International University

Abstract

Sickle cell anemia (SCA) is a hereditary blood disorder with profound implications for affected individuals, particularly in resource-limited settings such as Uganda. This review explores the multifaceted aspects of SCA in Uganda, focusing on epidemiology, challenges faced by individuals, coping strategies, healthcare disparities, and community support. The study incorporates a thorough examination of the genetic landscape, prevalence, and the impact of SCA on the quality of life in Uganda. Coping strategies and resilience play a pivotal role in mitigating the impact of SCA on affected individuals. This review critically evaluates the various coping mechanisms employed by individuals in Uganda and the resilience demonstrated in the face of chronic illness. It explores the psychological, social, and cultural dimensions of coping and resilience, shedding light on adaptive strategies that contribute to improved quality of life. This article aims to contribute valuable insights into the specific challenges faced by individuals with SCA in Uganda, offering a foundation for targeted interventions, improved healthcare policies, and increased awareness within both the medical community and the broader society.

Research topics

  • Hemoglobinopathies and Related Disorders
  • Iron Metabolism and Disorders

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1097/md.0000000000041062

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.